Eur Rev Med Pharmacol Sci 2012; 16 (6): 770-774

Serum paraoxonase, arylesterase activity and oxidative status in patients with obstructive sleep apnea syndrome (OSAS)

E. Baysal 1, S. Taysi 2, N. Aksoy 3, M. Uyar 4, F. Çelenk 1, Z.A. Karatas 1, M. Tarakcioglu 2, H. Bilinç 3, S. Mumbuç 1, M. Kanlikama 1

1 Department of Otolaryngology, 2 Biochemistry and 4 Pulmonary Diseases, Medical Faculty, Gaziantep University, Gaziantep (Turkey);

3 Department of Biochemistry, Medical Faculty, Harran University, Sanliurfa (Turkey)


INTRODUCTION: The aim of this study was to evaluate the serum paraoxonase (PON), arylesterase activities, lipid hydroperoxide (LOOH), sulfhydryl (-SH), and ceruloplasmin (Cp) levels, total antioxidant status (TAS), total oxidant status (TOS), and oxidative stress index (OSI) in adults with obstructive sleep apnea syndrome (OSAS) and to determine whether these oxidant and antioxidant levels can be used as OSAS markers. The results were compared with measurements from healthy control subjects.

MATERIALS AND METHODS: This study was a prospective, controlled trial including 26 OSAS patients and 35 healthy controls (61 subjects total). Peripheral venous blood samples were taken from the OSAS patients and from the healthy volunteers. The serum PON, arylesterase activities LOOH, -SH, Cp, TAS, TOS, and OSI levels were measured.

RESULTS: LOOH and Cp levels were higher in the OSAS group than in the control group (p < 0.01). The -SH levels were lower in the OSAS group than in the control group (p < 0.01). The PON and arylesterase enzyme activity levels were lower in the OSAS group than in the control group (p < 0.05). The TOS and OSI levels were significantly higher in the OSAS group (p < 0.01), while their TAS levels were significantly lower (p < 0.01) compared with the control group.

CONCLUSIONS: Patients with OSAS have increased systemic oxidative stress and reduced levels of circulating antioxidant enzymes. Oxidative stress appears to be an underlying condition associated with OSAS.

Corresponding Author: Elif Baysal, MD; e-mail: baysalelif@yahoo.com

To cite this article

E. Baysal 1, S. Taysi 2, N. Aksoy 3, M. Uyar 4, F. Çelenk 1, Z.A. Karatas 1, M. Tarakcioglu 2, H. Bilinç 3, S. Mumbuç 1, M. Kanlikama 1
Serum paraoxonase, arylesterase activity and oxidative status in patients with obstructive sleep apnea syndrome (OSAS)

Eur Rev Med Pharmacol Sci
Year: 2012
Vol. 16 - N. 6
Pages: 770-774